Modulation of NK, T, & B cell subpopulations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma

Rao P., Samur M., Talluri S., Derebail S., Potluri L., Haas E., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.10, 2019 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 19 Sayı: 10
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clml.2019.09.279
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: immunophenotype, Pomalidomide, Progression-free survival
  • Ankara Üniversitesi Adresli: Evet